首页> 美国卫生研究院文献>Respiratory Research >Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

【2h】

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

机译：在美国使用吡非尼酮和nintedanib相关的患者和部位特征；肺纤维化基金会患者登记处登记的特发性肺纤维化患者的分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patient characteristics by anti-fibrotic use and by specific medication

机译：通过抗纤维化和特殊药物治疗的患者特征

著录项

期刊名称 Respiratory Research
作者
Colin H. Holtze; Elizabeth A. Freiheit; Susan L. Limb; John L. Stauffer; Karina Raimundo; Wayne T. Pan; Kevin R. Flaherty; Hyun J. Kim;
展开▼
作者单位

展开▼
年(卷),期 2020(21),-1
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词
Idiopathic pulmonary fibrosis; Therapeutics; Clinical decision-making;

机译：特发性肺纤维化;治疗方法;临床决策;

相似文献

外文文献
中文文献
专利

1. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry [J] . Colin H. Holtze, Elizabeth A. Freiheit, Susan L. Limb, Respiratory Research . 2020,第1期

机译：与Pirfenidone和Nintedanib在美国的患者和网站特征;患有肺纤维化基患者登记处的特发性肺纤维化患者分析
2. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib [J] . Zhang Yingwei, Jones Kirk D., Achtar-Zadeh Natalia, Histopathology: Official Journal of the British Division of the International Academy of Pathology . 2019,第2期

机译：用Pirfenidone或尼宁尼治疗患者特发性肺纤维化肺的组织病理学和分子分析
3. Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study [J] . Progress in Artificial Intelligence . 2020,第2期

机译：尼丁胺治疗已从Pirfenidone治疗切换的特发性肺纤维化患者：回顾性案例系列研究
4. Acoustic evaluation of pirfenidone on patients with combined pulmonary fibrosis emphysema syndrome [C] . Sonia Charleston-Villalobos, Norma Castañeda-Villa, Ramón Gonzàlez-Camarena, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：吡非尼酮对合并肺纤维化性肺气肿综合征的声学评价
5. Correlation of Vascular Leak Measured Using Gadofosveset-Enhanced Lung Magnetic Resonance Imaging with Radiographic and Physiologic Measures of Fibrosis in Patients with Idiopathic Pulmonary Fibrosis. [D] . Liang, Lloyd. 2018

机译：特发性肺纤维化患者使用Gadofosveset增强肺磁共振成像测得的血管渗漏与纤维化的放射学和生理学指标的相关性。
6. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis [O] . Manon Belhassen, Faustine Dalon, Maëva Nolin, 2021

机译：接受Pirfenidone或Nintedanib的患者对特发性肺纤维化的比较结果
7. ASSOCIATION BETWEEN CLINICAL OUTCOMES AND BASELINE BMI OR ANNUALIZED WEIGHT LOSS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ENROLLED IN THE PULMONARY FIBROSIS FOUNDATION PATIENT REGISTRY [O] . Joyce Lee, Adam Martin-Schwarze, Elizabeth Freiheit, 2020

机译：患有特发性肺纤维化患者的临床结果与基线BMI或年化减肥之间的关联，患有肺纤维化基础患者登记处的患者

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

摘要

著录项

相似文献

相关主题

期刊订阅